Protocol·One

PT-141 · For post-SSRI sexual dysfunction

PT-141 for post-SSRI sexual dysfunction

SSRI killed your sex drive. PT-141 a real fix?

A-Tier Sexual Health Off-label · emerging

New to peptides? Start with the foundations ->

Why people use PT-141 for post-SSRI sexual dysfunction

SSRI killed your sex drive. PT-141 a real fix? The short answer: yes, this is one of the more-discussed uses for PT-141 - but the evidence quality and the right protocol depend on what you're actually trying to fix.

This page covers what's known, what's not, and what the editorial take is for normal humans considering PT-141 for post-SSRI sexual dysfunction.

What the evidence says

Evidence tier: Off-label · emerging. Off-label clinical use with emerging evidence; not FDA-approved for this indication specifically.

  • PSSD (post-SSRI sexual dysfunction) is poorly understood and lacks approved treatments.
  • PT-141's central nervous system mechanism may bypass the SSRI-affected pathway.
  • Anecdotal reports promising; no RCTs specific to PSSD.

Protocol notes

Standard PT-141 dosing. Coordinate with prescribing psychiatrist.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

  • Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
  • Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
  • Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free

Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine